Otofa® [Rifamycin]
Bouchard Laboratory
654 Items
2019-09-19
- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Clinical Pharmacology
Wide spectrum antibacterial, antibacterial, bactericidal. Otofa suppresses the synthesis of microbial cell RNA by forming a stable complex with DNA-dependent RNA polymerase.
Indications
Acute and chronic otitis (including with isolated purulent lesions of the eardrum and its perforations), conditions after operations on the middle ear.
Composition
100 ml ear drops contain:
Active ingredient: rifamycin sodium 2.6 g, which corresponds to 2,000,000 IU;
Excipients: macrogol 400 - 25 g, ascorbic acid - 500 mg, disodium edetate - 12 mg, potassium disulfite - 150 mg, lithium hydroxide - 135 mg, purified water - up to 100 ml.
No customer reviews for the moment.
Dosage and Administration
Otof is applied topically, buried in the external auditory canal; Before use, the bottle is warmed by holding it in your hand. 5 drops (for children - 3 drops), 3 times a day or twice a day, are poured into the external auditory canal for several minutes. Course - 1-3 days (no more).
Adverse reactions
Pink coloring of the eardrum (visible when otoscopy).
Contraindications
Hypersensitivity.
Special instructions
Rifampicin resistant strains may occur. Otofa contains sulfites.
- Brand name: Otofa
- Active ingredient: Rifamycin
- Dosage form: Ear drops
- Manufacturer: Bouchard Laboratory
- Country of Origin: France
- QSAR Modeling of Antimycobacterial Activity and Activity Against Other Bacteria of 3-Formyl Rifamycin SV Derivatives
- Production of rifamycin B and SV by free and immobilized cells of Amycolatopsis mediterranei
- Model-based optimization of feeding recipe for rifamycin fermentation
- Recent trends in rifamycin research
- Fluorescence quenching of serum albumin by rifamycin antibiotics and their analytical application
- Optimization of rifamycin B fermentation in shake flasks via a machine-learning-based approach
- Structured kinetic model to represent the utilization of multiple substrates in complex media during rifamycin B fermentation
- Aeration-agitation studies on the rifamycin fermentation
- Resolution of Binary Mixtures of Rifamycin SV and Rifampicin by UV/VIS Spectroscopy and Partial Least-Squares Method (PLS)
- A Homologue of the Mycobacterium tuberculosis PapA5 Protein, Rif-Orf20, Is an Acetyltransferase Involved in the Biosynthesis of Antitubercular Drug Rifamycin B by Amycolatopsis mediterranei S699
- Expeditious Asymmetric Synthesis of a Stereoheptad Corresponding to the C(19)–C(27)-Ansa Chain of Rifamycins: Formal Total Synthesis of Rifamycin S
- ChemInform Abstract: A General and Stereocontrolled Strategy for the Iterative Assembly of Enantiopure Polypropionate Subunits: Synthesis of the C19—C28 Segment of Rifamycin S from a Single Chiron.
- ChemInform Abstract: Synthesis and Activity Studies on 3-(Carboxyalkylthio)rifamycin S Derivatives.
- ChemInform Abstract: Synthesis of Stereopentad Subunits of Zincophorin and Rifamycin-S Through Use of Chiral Allenyltin Reagents.
- ChemInform Abstract: Oxabicyclo[3.2.1]octenes in Organic Synthesis—Direct Ring Opening of Oxabicyclo[3.2.1] Systems Employing Silyl Ketene Acetals in Concentrated Solution of Lithium Perchlorate—Diethyl Ether: Application to the Synthesis of the C(19)—C(27) Fragment of Rifamycin S.
- ChemInform Abstract: Efficient Strategy for the Synthesis of Stereopentad Subunits of Scytophycin, Rifamycin S, and Discodermolide.
- New Insights into Rifamycin B Biosynthesis: Isolation of Proansamycin B and 34a-Deoxy-rifamycin W as Early Macrocyclic Intermediates Indicating Two Separated Biosynthetic Pathways.
- Rifamycin — Mode of Action, Resistance, and Biosynthesis
- Bactericidal Efficacy of ABI-0043, a Novel Rifamycin, in a Murine Pneumococcal Pneumonia Model.
- Effects of the Interaction of Rifamycin SV with Serum Albumins on the Resonance Rayleigh Scattering Spectra and Their Analytical Application
- Isotachophoretic analysis of the pH dependent carrier properties of bovine serum albumin for rifamycin AF/013
- Zur Kenntnis von Rifamycin-S.-Reaktionen des Ansaringes. Modifikationen von Antibiotica, 8. Mitteilung [1]
- Zur Kenntnis von Rifamycin-S. Reaktionen des chinoiden Nucleus. Modifikationen von Antibiotica, 9. Mitteilung [1]
- Zuordnung des 13C-NMR.-Spektrums von Rifamycin-S Aufgrund der selektiven Protonen-Entkopplung
8 other products in the same category:
arrow_upward